Skip to main content
Premium Trial:

Request an Annual Quote

Sigma-Proligo, Agilent, BioIT Alliance, GE Healthcare, BAC, Millipore, Stem Cell Science, Beckman

Sigma-Proligo Opens Office Near Paris
Sigma-Proligo, the RNAi and PCR division of Sigma-Aldrich, last week said that it has opened offices near Paris.
The company said its newly acquired 2,000-square-foot facility in the Genopole d’Evry biopark will enable it to advance oligonucleotide production.
Sigma-Proligo specializes in nucleic acid synthesis and holds patents in siRNA gene silencing. The firm employs 65 people in France, the majority of whom are researchers, according to Sigma.
Sigma-Aldrich’s operations manager for Evry, Khalil Arar, predicts the RNAi market has a compound annual growth rate of 14 percent, and expects the new facilities will help the company meet that new demand.

Agilent Joins BioIT Alliance, Licenses Bioinformatics Products to NCI
Agilent Technologies has joined the BioIT Alliance, the company said last week.
Agilent will participate in the Alliance's latest application, called the Biomarkers Project, by focusing on problematic biomedical bottlenecks. The Biomarkers Project addresses complexity in the process of identifying and validating biomarkers.
The BioIT Alliance is a diverse group of IT and biotech companies working with Microsoft to advance biomedical information technology. It deals with issues such as data-capture and data-integration challenges.
Software company QL2 also joined the Alliance last week.
In a separate announcement this week, Agilent said that the National Cancer Institute has purchased a full site license to its bioinformatics products.
The NCI will use Agilent's GeneSpring, CGH Analytics, Agilent Chip Analytics, and GeneSpring GT platforms for research and analysis.
Financial details were not disclosed.

GE Healthcare, BAC to Develop Chromatography Media
GE Healthcare and BAC will collaborate on developing new affinity chromatography media for human antibodies and adeno-associated virus viral vector purification, BAC said last week.
The partners expect to launch the first products from the collaboration next year through GE Healthcare’s custom designed media business.
Terms of the agreement were not disclosed.

Millipore to Develop, Sell SCS’ Serum-Free Media
Millipore said this week that it would develop and market Stem Cell Sciences’ serum-free media for growing human embryonic stem cells.
According to Millipore, the media will be “the first product available in the industry that offers improved methods for growing hESCs without the need for animal serum.”
Millipore will sell the media under the brand name HEScGRO Embryonic Stem Cell Medium. The firm expects to commercialize the product by the end of this year.
SCS will receive royalties on future sales of the product. Financial terms of the agreement were not disclosed.

Beckman to Pay $.15 Dividend
Beckman Coulter will pay a $.15 per-share dividend on Nov. 10 to all stockholders of record on Oct. 23.
It will be the 70th consecutive quarter in which Beckman has paid a dividend to its shareholders.

The Scan

Ancient Greek Army Ancestry Highlights Mercenary Role in Historical Migrations

By profiling genomic patterns in 5th century samples from in and around Himera, researchers saw diverse ancestry in Greek army representatives in the region, as they report in PNAS.

Estonian Biobank Team Digs into Results Return Strategies, Experiences

Researchers in the European Journal of Human Genetics outline a procedure developed for individual return of results for the population biobank, along with participant experiences conveyed in survey data.

Rare Recessive Disease Insights Found in Individual Genomes

Researchers predict in Genome Medicine cross-population deletions and autosomal recessive disease impacts by analyzing recurrent nonallelic homologous recombination-related deletions.

Genetic Tests Lead to Potential Prognostic Variants in Dutch Children With Dilated Cardiomyopathy

Researchers in Circulation: Genomic and Precision Medicine found that the presence of pathogenic or likely pathogenic variants was linked to increased risk of death and poorer outcomes in children with pediatric dilated cardiomyopathy.